Objective: we assessed the association between baseline eosinophil cationic protein (ECP) levels, a sensitive
marker of eosinophil activation, and clinical outcome in patients undergoing bare metal stent (BMS)
Methods: basal ECP levels were measured in 110 patients (69±11 years, 88 men) undergoingBMSimplantation.
Major adverse cardiac events (MACEs), defined as cardiac death, non-fatal myocardial infarction,
or clinically-driven target lesion revascularization, were registered at 24-month follow-up.
Results: eighteen (16.4%) patients had MACEs and showed higher ECP levels compared with those without
MACEs [20.1 (9.8 47.3) vs. 9.5 (5.0 27.2) g/L, p = 0.02]. At follow-up, ECP level >11 g/L was the only
significant predictor of MACEs (HR 3.5, 95% CI 1.1 10.4, p = 0.03).
Conclusion: basal ECP levels are associated with MACEs after BMS implantation, suggesting that an
allergic-mediated inflammation against the metal could explain some adverse reactions occurring after
- Bare metal stents
- Eosinophil cationic protein